Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROOZBEH SHARIF

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1396037008
CMS profile
688165
Location
NEDERLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,570.45

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,800.00 1
Food and Beverage $1,624.47 63
Travel and Lodging $1,145.98 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROOZBEH SHARIF

NPI 1396037008 · CMS profile ID 688165

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEDERLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396037008?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396037008?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396037008?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROOZBEH SHARIF, NPI 1396037008, CMS profile ID 688165, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396037008?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $6,570.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–66 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $7.3705/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629669 CMS
United Therapeutics Corporation $13.0505/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050947131 CMS
AstraZeneca Pharmaceuticals LP $16.8905/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015090753 CMS
Philips Electronics North America Corporation $14.6405/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024032611 CMS
GENZYME CORPORATION $7.1505/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629663 CMS
Baxter Healthcare $22.8604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000161331 CMS
GENZYME CORPORATION $31.6904/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629603 CMS
GENZYME CORPORATION $22.1604/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629621 CMS
Inspire Medical Systems, Inc. $22.3703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058855589 CMS
GENZYME CORPORATION $8.4703/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629591 CMS
Baxter Healthcare $15.4303/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000161321 CMS
GlaxoSmithKline, LLC. $16.7903/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002165231 CMS
GENZYME CORPORATION $20.3403/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629567 CMS
GENZYME CORPORATION $5.9703/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629555 CMS
GENZYME CORPORATION $37.4001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629507 CMS
GENZYME CORPORATION $6.4701/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049629496 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $1,039.84 6
PY2022 $3,080.23 33
PY2023 $6,570.45 66
PY2024 $2,920.49 116
PY2025 $9,202.00 104

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $608,346.04 40
PY2024 Principal investigator $707,959.33 37
PY2023 Principal investigator $63,928.74 10
PY2022 Principal investigator $38,400.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $1,250.00 12/22/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119193
Principal investigator 1 GENZYME CORPORATION $3,125.00 12/08/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119177
Principal investigator 1 GENZYME CORPORATION $48,850.00 12/08/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119181
Principal investigator 1 GENZYME CORPORATION $375.00 12/08/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119186
Principal investigator 1 GENZYME CORPORATION $500.00 12/08/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119189
Principal investigator 1 GlaxoSmithKline, LLC. $725.00 11/25/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117631
Principal investigator 1 GlaxoSmithKline, LLC. $725.00 11/25/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117660
Principal investigator 1 SANOFI US SERVICES INC. $1,620.00 11/24/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226097810
Principal investigator 1 GENZYME CORPORATION $25,550.00 11/04/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
Evaluate how dupilumab can alter the trajectory of COPD by modifying disease progression No dispute reported 06/30/2026 1226097763
Principal investigator 1 SANOFI US SERVICES INC. $29,000.00 10/27/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226097721
Principal investigator 1 SANOFI US SERVICES INC. $1,839.00 10/14/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226097714
Principal investigator 1 GENZYME CORPORATION $44,900.00 08/18/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119172
Principal investigator 1 SANOFI US SERVICES INC. $4,313.00 08/18/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226097636
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 07/21/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226097578
Principal investigator 1 GENZYME CORPORATION $3,400.00 07/14/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119167
Principal investigator 1 SANOFI US SERVICES INC. $1,839.00 07/14/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226097556
Principal investigator 1 GENZYME CORPORATION $17,110.00 07/02/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226119163
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,000.00 06/23/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552381
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,000.00 06/11/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185552377
Principal investigator 1 ModernaTX, Inc. $10,367.83 06/02/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252967149
Principal investigator 1 SANOFI US SERVICES INC. $2,834.00 05/29/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226085485
Principal investigator 1 SANOFI US SERVICES INC. $12,826.00 04/23/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226085436
Principal investigator 1 GlaxoSmithKline, LLC. $4,076.40 04/17/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117620
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,000.00 04/09/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552387
Principal investigator 1 AstraZeneca UK Limited $54,730.35 03/24/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS, LLC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185552383
Principal investigator 1 ModernaTX, Inc. $8,000.00 03/24/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252967151
Principal investigator 1 ModernaTX, Inc. $2,100.00 03/24/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252967155
Principal investigator 1 GlaxoSmithKline, LLC. $19,300.10 03/20/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117606
Principal investigator 1 SANOFI US SERVICES INC. $6,731.50 03/17/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226119114
Principal investigator 1 SANOFI US SERVICES INC. $15,939.00 03/04/2025 Non-covered Recipient Entity
Rex Clinical Trials Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226085406
Principal investigator 1 GlaxoSmithKline, LLC. $17,290.80 02/20/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117643
Principal investigator 1 SANOFI US SERVICES INC. $5,493.00 02/18/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226119118
Principal investigator 1 ModernaTX, Inc. $4,565.80 02/14/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252967153
Principal investigator 1 GlaxoSmithKline, LLC. $1,562.00 01/30/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117613
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/30/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117637
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 01/30/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117650
Principal investigator 1 AstraZeneca UK Limited $40,782.66 01/22/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS, LLC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185552379
Principal investigator 1 SANOFI US SERVICES INC. $3,757.50 01/21/2025 Non-covered Recipient Entity
Rex Tha Clinical Trials Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226119108
Principal investigator 1 GlaxoSmithKline, LLC. $93,035.40 01/16/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192111877
Principal investigator 1 GlaxoSmithKline, LLC. $71,132.70 01/16/2025 Non-covered Recipient Entity
REX CLINICAL TRIALS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192117627